The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Moderna.Inc; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Jeeyun Lee
Consulting or Advisory Role - Amgen; AstraZeneca; Daichi Sankyo; Guardant Health AMEA; Immunoncia; Mirati Therapeutics; Trutino Biosciences
Research Funding - AstraZeneca; Merck Sharp & Dohme; Samsung Biopeis; Samsung Biopeis
 
Paulo Hoff
Leadership - Oncologia D’Or
Stock and Other Ownership Interests - Oncostar
Honoraria - Bayer Health (I); United medical (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (I); EMS; EMS; Exelixis (I); Lilly (I); United Health Group (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BMS Brazil (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Exelixis (Inst); Lilly (I); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Elizabeth Smyth
Employment - HCA International (I)
Honoraria - Bristol-Meyer Squibb; Novartis; Pfizer; SERVIER
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Merck Serono; MSD; Novartis; Roche; SERVIER; Turning Point Therapeutics; Viracta Therapeutics; Zymeworks
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Meyers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen
 
Daniel Barrios
Employment - Daiichi Sankyo
Honoraria - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Kojiro Kobayashi
Employment - DAIICHI SANKYO CO., LTD.; Sumitomo Dainippon Pharma (I)
Stock and Other Ownership Interests - Daiichi Sankyo
 
Yasuyuki Okuda
Employment - Daiichi Sankyo
 
Takahiro Kamio
Employment - Daiichi Sankyo/Astra Zeneca
 
Yelena Janjigian
Stock and Other Ownership Interests - Inspirna
Honoraria - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; eChinaHealth; Ed Med Resources (OncInfo); Eisai; Geneos; Genzyme; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Lilly; Lynx Health; Master Clinician Alliance; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Silverback Therapeutics; Suzhou Liangyihui Network Technology; Talem Health; TotalCME; WebMD; Zymeworks
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Ed Med Resources (OncLive); Eisai; Geneos; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Silverback Therapeutics; WebMD; Zymeworks
Research Funding - Arcus Biosciences (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Inspirna (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Stand up to Cancer (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Giants of Cancer Care; Research to Practice